Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 4Completed 3Withdrawn 2Active not recruiting 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Dermatologic 3Thoracic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 8Neoplasm Metastasis 7Lung Neoplasms 6Rectal Neoplasms 5Sarcoma 4Prostatic Neoplasms 4Melanoma 4Colonic Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thymoma 2Neoplasms 2Mouth Neoplasms 2Head and Neck Neoplasms 2Carcinoma 2Adenomatous Polyposis Coli 2Uterine Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paranasal Sinus Neoplasms 1Papilloma 1Pain 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Sarcoma × Celecoxib × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

NCT01143545 2020-03-03

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
10 enrolled
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Esophageal Neoplasms, Lung Neoplasms, Sarcoma, Thymoma

NCT01313429 2020-03-03

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
19 enrolled
DermatologicSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Sarcoma

NCT01341496 2018-07-05

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
41 enrolled
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡